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During vessel sprouting, a migra-tory endothelial tip cell guides the 
sprout, while proliferating stalk cells elon-
gate the branch. Tip and stalk cell pheno-
types are not genetically predetermined 
fates, but are dynamically interchange-
able to ensure that the fittest endothe-
lial cell (EC) leads the vessel sprout. 
ECs increase glycolysis when forming 
new blood vessels. Genetic deficiency of 
the glycolytic activator PFKFB3 in ECs 
reduces vascular sprouting by impairing 
migration of tip cells and proliferation 
of stalk cells. PFKFB3-driven glycolysis 
promotes the tip cell phenotype during 
vessel sprouting, since PFKFB3 overex-
pression overrules the pro-stalk activ-
ity of Notch signaling. Furthermore, 
PFKFB3-deficient ECs cannot compete 
with wild-type neighbors to form new 
blood vessels in chimeric mosaic mice. 
In addition, pharmacological PFKFB3 
blockade reduces pathological angiogen-
esis with modest systemic effects, likely 
because it decreases glycolysis only par-
tially and transiently.
Results and Discussion
The vasculature is of crucial impor-
tance for delivering oxygen and nutrients 
to tissues. When this supply is limiting, 
new blood vessels are formed. This process 
(termed angiogenesis) is not only critical 
during embryonic development, but also 
promotes pathological conditions such as 
cancer and inflammatory disorders.1 Dur-
ing vessel sprouting, pro-angiogenic fac-
tors such as VEGF promote the induction 
of a migratory endothelial tip cell, while 
proliferating endothelial stalk cells elon-
gate the sprout.1 Most anti-angiogenic 
therapies currently approved for clinical 
use or in (pre)-clinical development block 
molecules like VEGF. However, anti-can-
cer therapies targeting VEGF signaling 
suffer from resistance and toxicity, neces-
sitating the development of novel anti-
angiogenic strategies.2,3 Research over the 
past decades has identified several genetic 
signals that regulate angiogenesis, but the 
role of endothelial cell (EC) metabolism 
in angiogenesis has not been intensely 
studied.
ECs remain quiescent for years, but 
can rapidly start to proliferate and migrate 
when stimulated by angiogenic signals. 
These processes require energy and molec-
ular building blocks for biomass duplica-
tion. Since angiogenic ECs have different 
metabolic needs than quiescent ECs, it has 
been postulated that a metabolic switch 
accompanies the angiogenic switch.4,5 
However, little is known about EC metab-
olism in relation to vessel branching and 
on which metabolic pathways ECs rely to 
form new vessels.
ECs line blood vessels and, thus, have 
immediate access to oxygen in the blood. 
Yet, they do not take advantage of this 
availability of oxygen to rely on oxidative 
metabolism, but instead are highly gly-
colytic and generate up to 85% of their 
ATP from glycolysis.4,6 To evaluate the 
importance of glycolysis in vessel sprout-
ing, we used pharmacological blockade or 
genetic silencing of phosphofructokinase-
fructose-2,6-bisphosphatase-3 (PFKFB3), 
Keywords: endothelial cell, angiogenesis, 
glycolysis, metabolism, vessel sprouting
Submitted: 12/09/2013
Accepted: 12/12/2013
http://dx.doi.org/10.4161/cc.27519
*Correspondence to: Peter Carmeliet; 
Email: peter.carmeliet@vib-kuleuven.be
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Cell Cycle 17
 EXTRA VIEWS EXTRA VIEWS
an enzyme producing fructose-2,6-bi-
phosphate, which is a potent allosteric 
activator of the rate-limiting glycolytic 
enzyme phosphofructokinase-1. PFKFB3 
inhibition in ECs reduced glycolysis, but 
by no more than 40%, and did not cause 
general energy hypo-metabolism.4 None-
theless, even this partial inhibition of gly-
colysis sufficed to reduce EC proliferation 
and migration, and vessel sprouting from 
EC spheroids in vitro.4,5 Furthermore, 
zebrafish treated with the pharmacologi-
cal PFKFB3 blocker 3-(3-pyridinyl)-1-
(4-pyridinyl)-2-propen-1-one (3PO) 
and mice lacking PFKFB3 in ECs dis-
played vascular sprouting and branch-
ing defects.4,5 3PO was not cytotoxic for 
ECs, and its anti-angiogenic effects were 
reversible.4,5
Consistent with reports that PFKFB3-
driven glycolysis promotes cellular pro-
liferation,7,8 endothelial loss of PFKFB3 
reduced EC proliferation and rendered 
stalk cells hypo-proliferative.4 However, 
blockade or loss of PFKFB3 in ECs also 
impaired various tip cell functions, such 
as directional migration and filopodia and 
lamellipodia formation, processes that 
require actin cytoskeletal remodeling.4 
Blockade of PFKFB3-driven glycolysis 
also affected additional processes of EC 
dynamics, involving cytoskeleton remod-
eling. Indeed, for a cell to establish contact 
with another cell, it must alter its shape. 
Since a sphere has a low surface tension, 
a cell preferably adopts a spheroid shape, 
and any deviation from this shape, such 
as when a cell is spreading or establishes 
cell–cell contacts, requires “adhesion 
energy”.9 Time-lapse imaging of sparsely 
plated GFP+ ECs showed that control cells 
established long-lasting cell–cell contacts 
with each other (Fig. 1A). In contrast, 
PFKFB3-silenced cells (using published 
methods4) only made transient “kiss and 
run” contacts, and after brief touching, 
they disconnected without maintaining 
stable contact (Fig. 1B). This was due 
to the fact that PFKFB3-silenced ECs 
formed only small, irregular, and transient 
lamellipodial projections (Fig. 1B), as 
quantified earlier.4
Tip and stalk cell phenotypes are not 
fixed predetermined cell fates, but instead 
are interchangeable phenotypes. Hence, a 
stalk cell can plastically differentiate to a 
tip cell over a period of 6 h.10 ECs must thus 
be competitive to reach the tip position. 
We recently reported that PFKFB3 defi-
ciency impairs tip cell competitiveness 
during embryonic vascular development 
in the hindbrain.4 The process of tip and 
stalk cell differentiation is under tight 
control of genetic signaling by VEGF (a 
pro-tip signal) and Notch (a pro-stalk 
signal), among other angio-modulatory 
signals.1 Use of mosaic EC spheroids and 
transgenic zebrafish showed that overex-
pression of PFKFB3 provided ECs a com-
petitive advantage for the tip position, not 
only in baseline conditions, but even when 
Notch signaling was increased in trans-
genic ECs.4 The finding that PFKFB3 
overexpression was capable of overruling 
the pro-stalk activity of Notch and pro-
moted stalk cells to become tip cells is 
remarkable, as no other signal has been 
documented to overcome the strong pro-
stalk activity of Notch. These data thus 
show that glycolysis provides a competi-
tive advantage for ECs to reach the tip and 
establish that metabolism (glycolysis) co-
determines vascular branching, in parallel 
to genetic signals like VEGF and Notch.4 
Importantly, the role of PFKFB3 in vas-
cular branching did not rely on a change 
in the genetic angiogenic signature, as the 
expression levels of pro-tip 
signals (such as VEGF) 
and pro-stalk signals (such 
as Notch) were unaffected 
when PFKFB3 levels were 
altered.4 Conversely, VEGF 
or Notch signaling regu-
lated PFKFB3 and glycoly-
sis levels, indicating that 
glycolysis is downstream 
and required for angiogenic 
signaling.4
The tip cell responses 
that were affected by 
PFKFB3 blockade relied 
on remodeling of the actin 
cytoskeleton,4 a process 
that requires rapid produc-
tion of large amounts of 
ATP by glycolysis in ECs. 
Indeed, bulky mitochon-
dria were excluded from the 
thin lamellipodia and nar-
row filopodia, and altering 
mitochondrial respiration 
did not affect vessel sprout-
ing.4 In contrast, PFKFB3 
Figure 1. PFKFB3 blokade impairs cell–cell contact and vessel formation. (A and B) Representative snapshot images 
of time-lapse imaging, showing that control cells make long lasting cell–cell contact (A), while PFKFB3-silenced cells 
make only transient contact (B). (C–J) Representative images of the postnatal aorta (open book preparation) of chi-
meric PFKFB3WT/Cherry (C–F) and PFKFB3KO/Cherry pups (G–J), stained for the endothelial nuclear marker Erg (green, C, 
E–G, I, and J) or expressing mCherry (red, labeling transgenic cells in D–F and H–J). (F and J) show a high magni-
!cation of the insets in (E and I). (C–F) A fraction of the ECs are PFKFB3WT/Cherry (arrowheads, red cells oriented in the 
vertical axis); likewise, a fraction of the smooth muscle cells is also PFKFB3WT/Cherry (red cells oriented in the horizontal 
axis). (G–J) All ECs are wild-type (host-derived), while PFKFB3KO/Cherry ECs are not detected (evidenced by the absence 
of vertically oriented red cells), even though other PFKFB3KO/Cherry cell types are present (smooth muscle cells in red, 
oriented in the horizontal axis). These !ndings indicate that PFKFB3KO/Cherry ECs are out-competed by wild-type ECs 
originating from the wild-type host blastocyst. The white arrow indicates the direction of blood "ow. Open book 
preparation: the ECs are facing upwards (the adventitia is facing downwards).
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and other glycolytic enzymes were pres-
ent in the perinuclear cytosol in quiescent 
ECs, but were relocated to lamellipodia in 
migrating ECs.4 ATP biosensor imaging 
revealed ATP hotspots in motile lamel-
lipodia, which were reduced by silencing 
of PFKFB3 but not by mitochondrial 
poisons.4 At the molecular level, PFKFB3 
interacted with F-actin at increased levels 
in the leading membrane ruffles of lamel-
lipodia of motile ECs.4 Since binding of 
various glycolytic enzymes to F-actin 
promotes the formation of their active 
tetramerized state and favors the forma-
tion of an efficient assembly line, whereby 
the product of one glycolytic enzyme 
becomes the substrate of the next glyco-
lytic enzyme,11 compartimentalization of 
glycolytic enzymes with F-actin provides a 
mechanistic explanation of how glycolysis 
fuels EC tip functions.4
The impaired tip and stalk cell activi-
ties of ECs lacking PFKFB34 prompted 
us to investigate whether PFKFB3-defi-
cient (PFKFB3KO) ECs would be able to 
compete with wild-type (WT) ECs for 
the formation and maintenance of blood 
vessels after birth. We therefore used 
PFKFB3-deficient (PFKFB3KO) ES cells, 
stably expressing a CherryRed marker, 
to visualize transgenic cells (PFKFB3KO/
Cherry).4 Wild-type (PFKFB3WT) ES cells 
transfected with CherryRed were used as 
a control (PFKFB3WT/Cherry).4 PFKFB3KO/
Cherry or PFKFB3WT/Cherry ES cells were then 
injected into WT blastocysts to gener-
ate highly (>90–95%) mosaic chimeras. 
We then assessed the contribution of 
PFKFB3KO/Cherry or PFKFB3WT/Cherry ECs 
to the formation and maintenance of the 
dorsal aorta at postnatal day 5 by stain-
ing for the EC-specific transcription factor 
Erg. Surprisingly, no PFKFB3KO/Cherry ECs 
were detectable in the aorta; even though 
PFKFB3WT/Cherry ECs were abundantly 
present (Fig. 1C–J). This was remarkable, 
since PFKFB3KO/Cherry ES cells differenti-
ated to smooth muscle cells, which were 
readily identified by their orientation, 
perpendicular to the alignment of ECs in 
the direction of blood flow (Fig. 1C–J). 
These findings indicate that ECs, lack-
ing PFKFB3, were outcompeted during 
embryonic development by their WT 
neighbors originating from the host blasto-
cyst cells, likely because of their impaired 
tip and stalk cell functions, overall illus-
trating the importance of PFKFB3-driven 
glycolysis for ECs for vessel formation.
Overall, these findings show that not 
only genetic signals, but also metabolism 
regulates vessel branching. This insight 
raised the question whether PFKFB3-
driven glycolysis might be a target for 
inhibiting angiogenesis in pathologi-
cal conditions. Indeed, pharmacological 
PFKFB3 blockade, using the compound 
3PO, reduces vessel sprouting in vitro and 
pathological angiogenesis in models of 
choroidal neovascularization, retinopathy 
of prematurity and inflammatory skin and 
bowel diseases.5 Remarkably, however, 
treatment of adult mice (in which most 
vessels are quiescent) with 3PO for 15 d did 
not affect the healthy established vascula-
ture in the retina (Fig. 2A and D); neither 
did it change the vascular area in other 
organs such as the kidney (Fig. 2B and E) 
and the heart (Fig. 2C and F). 3PO also 
did not affect the perfusion of retinal ves-
sels (Fig. 2G–L) or cause vessel wall leak-
age of various organs in adult healthy mice 
(Fig. 2M and N). These findings thus 
illustrate that proliferating and migrat-
ing ECs during pathological angiogenesis 
are more susceptible to PFKFB3 blockade 
than quiescent ECs in established vessels, 
in accordance with reports that sprouting 
ECs have higher levels of glycolysis than 
quiescent ECs, and that 3PO inhibits the 
hypermetabolism associated with sprout-
ing ECs.5
We also explored whether 3PO treat-
ment induced systemic effects, given that 
glycolysis is part of the central metabolism 
in multiple other cell types. We therefore 
treated adult healthy mice for 15 d with 
the same dose of 3PO that decreased 
angiogenesis. The following effects were 
noticed. First, 3PO caused a <10% body 
weight loss and reduced red blood cell 
parameters by <10% (Table 1). Intestinal 
crypt stem cell proliferation was reduced 
by 18%, but crypts and villi were normal 
in morphology and size (Table 1), suggest-
ing that 3PO reduced but did not deplete 
the intestinal stem cell pool. Other param-
eters were not affected. For instance, 3PO 
did not induce striking differences in 
biochemical blood parameters (Table 1), 
nor did it induce histological abnormali-
ties in liver, muscle, colon, and kidney 
(Fig. 3A–H) or of the intestines, brain and 
heart (not shown). No overt signs of liver 
Table 1. Systemic e#ects of PFKFB3 blockade
DMSO control 3PO
Vascular parameters
̆Heart (endoglin+ area, % of total)
̆Kidney medulla (CD31+ area, % of total)
̆Kidney cortex (CD31+ area, % of total)
17.4 ± 0.7
15.8 ± 0.3
55.4 ± 2.8
15.8 ± 0.9
14.4 ± 0.6
54.2 ± 1.3
Liver parameters
̆ALT plasma level (U/L)
̆AlcP plasma levels (U/L)
̆γ-GT plasma levels (U/L)
̆Bilirubine plasma levels (mg/dL)
12 ± 0.5
33 ± 3
<3
<0.18
16 ± 1.4
33 ± 11
<3
<0.18
Renal parameters
̆Ureum (mg/dL)
̆Creatinine (mg/dL)
53 ± 6.5
<0.06
55 ± 6.2
<0.06
Small intestine parameters
̆Crypt cell proliferation (BrdU+ cells, % of total)
̆Villus height (μm)
̆Crypt depth (μm)
28 ± 0.8
379 ± 8
70 ± 2
23 ± 0.8*
378 ± 17
69 ± 2.3
Hematological parameters
̆WBCs (×103/μL)
̆Platelets (×103/μL)
̆Hematocrit (%)
̆RBCs (×106/μL)
̆Hemoglobin (g/dL)
6.1 ± 1.1
564 ± 63
42 ± 0.3
8.9 ± 0.1
15.8 ± 0.2
5.4 ± 0.9
690 ± 64
39 ± 0.9
8.3 ± 0.2*
14.4 ± 0.3*
Values are mean ± SEM, n = 5. ALT, alanine aminotransferase; AlcP, alkaline phosphatase; γ-GT, 
γ-glutamyl transpeptidase; WBCs, white blood cell counts; RBCs, red blood cells; *P < 0.05 vs DMSO.
©
20
13
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Cell Cycle 19
inflammation were detected (Fig. 3I), and 
no signs of eye toxicity were observed as 
shown by staining for the glial cell marker 
GFAP (Fig. 3J) and quantification of 
the thickness of the retinal nuclear lay-
ers (Fig. 3K–M). Plasma creatine kinase 
(CK) levels were also not elevated, sug-
gesting normal cardiomyocyte viability 
(Fig. 3N). We also tested if 3PO affected 
the recovery from myelosuppression by 
doxorubicin, cisplatin, capecitabine, and 
sorafenib, administered at doses inhibit-
ing tumor growth. Treatment with 3PO 
slightly aggravated myelosuppression by 
cisplatin and sorafenib (at a single time 
point after 14 or 7 d, respectively), but 
white blood cell counts fully recovered in 
all 3PO-treated mice (Fig. 3O).
We explored the underlying reasons 
of why 3PO did not induce more severe 
adverse effects than perhaps initially 
anticipated. First, 3PO had a short half-
life (30 min)12 and reduced glycolysis only 
partially (by 35–40%) and transiently 
(during <6 h) in vivo, though 3PO was 
again effective in reducing glycolysis upon 
re-administration.5 Nonetheless, this tran-
sient partial decrease in glycolysis was suf-
ficient to block pathological angiogenesis,5 
thus providing a new paradigm that anti-
glycolytic therapy does not need to block 
glycolysis completely and permanently in 
ECs to impair angiogenesis. Second, given 
that cells need glycolysis to proliferate, 
we also hypothesized that quiescent cells 
or cells not relying critically on glycolysis 
would be less sensitive to PFKFB3-block-
ade. Indeed, 3PO did not affect glycolysis 
or survival of neurons and resident macro-
phages, known to have negligible PFKFB3 
levels (Table 2).13,14 In other cells, such 
as hepatocytes and adipocytes, 3PO 
reduced glycolysis, but their survival was 
not compromised, indicating that these 
cells did not critically rely on PFKFB3-
driven glycolysis as their predominant 
metabolic pathway and likely were able 
to compensatorily switch to another type 
of metabolism (Table 2). By contrast, 
rapidly proliferating cells, such as ECs or 
tumor cells, have high levels of glycolysis, 
and their glycolytic flux and proliferation 
were reduced by 3PO (Table 2). Taken 
together, PFKFB3-blockade primarily tar-
gets rapidly proliferating/migrating cell 
types that critically rely on glycolysis.
Overall, the partial, transient blockade 
of glycolysis sufficed to reduce sprouting, 
yet was less toxic than perhaps intuitively 
expected based on the widely held belief 
that many cell types require glycolysis. 
However, PFKFB3 inhibition does not 
indiscriminately affect any type of healthy 
cells, but primarily targets those cells that 
Figure 2. PFKFB3 blockade does not target the quiescent vasculature. (A–F) Vascular densities in 
the retina (A and D, isolectin B4), kidney (B and E, CD31) and heart (C and F, endoglin) were not 
a#ected by 15 d treatment of adult healthy mice with 3PO. (A–C) control, (D–F) 3PO. Scale bars: 
200 µm (A and D), 50 µm (B and E), and 100 µm (C and F). (G–L) Confocal images of dextran-FITC 
injected (G and J) and isolectin-B4 (H and K) stained retina of healthy mice that were treated with 
3PO (J–L) or vehicle (G–I) for 15 d showing that 3PO does not induce vessel leakiness in the quies-
cent vessels of the retina. (I and L) show the merged images. (M) Quanti!cation of the Evans blue 
dye leakage in heart, lung, liver, and kidney, showing no e#ect of 3PO treatment (50 mg/kg/day for 
4 d) on vessel leakiness (mean ± SEM, n = 5, P = NS). (N) Quanti!cation of FITC-dextran+ area in the 
kidney after injection of FITC-dextran (MW 40 000 Da) followed by saline perfusion 10 min later, 
showing no e#ect of 3PO treatment on vessel leakiness (mean ± SEM, n = 5, P = NS).
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rely on glycolysis as a critical metabolic 
pathway, such as proliferating and migrat-
ing cells. Noteworthy in this respect, the 
vast majority (>90%) of cells in a healthy 
adult are quiescent. The finding that ECs 
rely on glycolysis more than other cell 
types explains why ECs are more vulner-
able to PFKFB3 blockade. In addition, it 
is important to stress that 3PO treatment 
decreased glycolysis only partially and 
transiently. A more sustained and more 
complete inhibition of glucose metabolism 
by 80%, as obtained when treating ECs 
with the non-metabolizable glucose ana-
log 2-deoxy-D-glucose, is indeed more 
toxic, inducing cellular distress and killing 
ECs, ultimately, in particular in sprouting 
conditions.5
Figure 3. PFKFB3 blockade does not a#ect organ morphology and heart function. (A–H) No histological abnormalities were detected by H&E stain-
ing of the colon (A and E), liver (B and F), muscle (C and G), and kidney (D and H) of adult healthy mice treated for 15 d with 3PO. (A–D) control, 
(E–H) 3PO. (I) Quanti!cation of the CD45+ area in the liver, showing comparable numbers of in"ammatory cells upon 3PO treatment (50 mg/kg/day for 
15 d) (mean ± SEM, n = 5, P = NS). (J) Quanti!cation of the glial !brillary acidic protein (GFAP) positive area in the retina, showing similar number of glial 
cells and thus absence of gliosis upon 3PO treatment (50 mg/kg/day for 15 d) (mean ± SEM, n = 5, P = NS). (K–M) Quanti!cation of the thickness of the 
outer nuclear layer (ONL), outer plexiform layer (OPL), and inner nuclear layer (INL), showing no thinning of these retinal layers (a sign of neuroxocity) 
by 3PO (mean ± SEM, n = 5, P = NS). (N) Plasma creatine kinase levels showing similar levels after 3PO treatment (50 mg/kg/day for 15 d), suggesting 
normal cardiomyocyte viability (mean ± SEM, n = 10, P = NS). (O) White blood cell counts (WBCs) after treatment with the chemotherapeutics, cisplatin, 
capecitabine, doxorubicin, and the anti-angiogenic agent sorafenib at doses inhibiting tumor growth and angiogenesis, showing that 3PO aggravated 
the myelosuppressive toxicity only for cisplatin and sorafenib at a single time point, but WBCs in all 3PO-treated mice fully recovered (mean ± SEM; n = 
5; *P < 0.05 vs. ctrl; &P < 0.05 vs. day 0).
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In this respect, it is also noteworthy 
that only <2.5% of the total ATP in the 
body is produced by glycolysis,15 thus 
implying that most other cells rely on 
non-glycolytic mechanisms for energy 
homeostasis and that blocking glycolysis 
(certainly when only transiently and par-
tially) should not necessarily be expected 
to cause widespread cellular demise. In 
contrast, proliferating ECs, tumor cells16,17 
and activated T cells18 critically rely on 
high glycolysis levels. Hence, 3PO inhib-
ited their proliferation, thereby reducing 
pathological neovascularization, as well 
as tumor growth and inflammatory dis-
eases.18,19 Our findings are also consistent 
with reports that human hereditary muta-
tions in glycolytic genes are well tolerated 
as long as they do not deplete cellular ATP 
levels.20 Careful assessment of potential 
toxicity and identification of possible con-
tra-indications will nevertheless be critical 
to design anti-angiogenic therapy based 
on partial, transient glycolysis inhibition.
Experimental Methods
Cell culture
Primary cells
Human umbilical vein endothelial cells 
(HUVECs) were freshly isolated from dif-
ferent donors and cultured as described.4 
Murine hepatocytes were isolated using 
a 2-step collagenase perfusion technique 
and fixed after short-term culture for 6 h, 
as described.21 Murine macrophages were 
collected from the peritoneal cavity and 
cultured in RPMI (Invitrogen, Life Tech-
nologies) containing 10% FBS. Murine 
adipocytes were isolated from epididymal/
gonadal fat pads using 0.1% collagenase 
II, separated from the stromal vascular 
fraction via centrifugation, and were cul-
tured in DMEM/F12 supplemented with 
10% FBS.22 Neuronal cultures were pre-
pared from the cortices of embryonic day 
14 (E14) mice and maintained in serum-
free NeuroBasal medium (Gibco) contain-
ing 25 mM glucose.23 After 4 d in culture, 
8 µM cytosine arabinoside was added to 
prevent non-neuronal proliferation.
Tumor cell lines
CT2A murine glioblastoma cells were 
cultured in DMEM containing 10% FBS 
and 2 mM glutamine (Invitrogen, Life 
Technologies) supplemented with condi-
tioned medium obtained from CT2A cells. 
Murine endothelial cells, infected with an 
ecotropic retrovirus encoding SV40 large 
T 58–3 allele (MS1 hemangioma) and sub-
sequently infected with a second retrovirus 
encoding activated H-ras (SVR angiosar-
coma) were obtained from Dr Arbiser and 
cultured in DMEM with glutamine and 
10% FBS.24 All cells were routinely main-
tained in 5% CO2 and 95% air at 37 °C. 
Knockdown strategies
Transduction of lentiviral vectors 
encoding a PFKFB3 or a scrambled con-
trol shRNA were performed as described.4
In vitro assays
Live cell imaging
GFP+ control and PFKFB3-silenced 
ECs were plated on a glass bottom 24-well 
plate and images were acquired continu-
ously overnight at 37 °C using a Zeiss 
LSM 510 Meta NLO confocal microscope 
(LD Plan-Neofluor 20´/0.4 Korr M27 
objective). 
Proliferation and survival
Proliferation was quantified using 
[3H]-thymidine incorporation4 and sur-
vival was measured by determining the 
LDH release in the medium using the 
Cytotoxicity Detection Kit (Roche applied 
sciences). 
Glycolysis
Flux through glycolysis was deter-
mined as described.4
In vivo assays
Housing of mice and experimental 
procedures were approved by the Animal 
Care and Use Committee of the Univer-
sity of Leuven. 
Mouse mosaics
Chimeric pups were generated by 
injecting 15–20 wild-type or PFKFB3KO 
ES cells, stably transfected with mCherry, 
into CD-1 or FVB host blastocysts. 
Injected blastocysts were transplanted 
into 2.5 d pseudopregnant CD-1 foster 
mothers and allowed to develop to term. 
Aortas were dissected at postnatal day 5, 
fixed in 4% PFA, mounted as an open 
book preparation (by making a longitudi-
nal section to spread open the inner sur-
face of the aorta), and stained for anti-Erg 
(Santa Cruz Biotechnology) and isolectin 
GS-IB4-Alexa 488 (Molecular Probes).
4 
Images were captured with a Zeiss laser 
scanning LSM 780 microscope (Carl 
Zeiss). 
Analysis of systemic effects
General
C57BL/6 mice (Charles River) were 
used in all experiments. Adult (8-wk-old) 
mice were treated intraperitoneally with 
3PO for 15 d (50 mg/kg/day; dissolved 
in DMSO). Organs (heart, liver, intes-
tines, brains, lungs, kidneys, muscle, eyes) 
were dissected, embedded in paraffin, 
and stained with H&E and for CD105 
(endoglin), CD31, CD45, or GFAP as 
described.25,26 Crypt stem cell prolifera-
tion was assessed after BrdU injection and 
expressed as BrdU+ crypt cells relative 
Table 2. E#ects of 3PO on glycolysis, survival and proliferation of cells
Cell type Glycolysis E!ects of 3PO on
Glycolysis Survival (%)
Q
ui
es
ce
nt
neurons 651 ± 50 658 ± 65 109 ± 11
macrophages 367 ± 34 428 ± 16 121 ± 7
adipocytes 199 ± 13 120 ± 7* 107 ± 2
hepatocytes 219 ± 24 146 ± 11* 110 ± 15
Glycolysis Proliferation (%)
Pr
ol
ife
ra
tin
g HUVECs 1800 ± 37 1280 ± 57* 79 ± 2*
hemangioma (MS1) 3300 ± 60 2100 ± 43* 40 ± 3*
angiosarcoma (SVR) 6350 ± 288 3780 ± 23* 64 ± 1*
glioblastoma (CT2A) 4780 ± 110 3530 ± 67* 66 ± 3*
Data show the effect of 3PO treatment (20–40 µM) on glycolysis (nmol glucose/hr/mg protein) and 
survival (LDH release in medium; % of control) or proliferation (3H-thymidine incorporation; % of con-
trol) in different quiescent and proliferating cells. Values are mean ± SEM, n = 5 for adipocytes and 
hepatocytes, n = 4 for neurons and n = 3 for all other cell types. *P < 0.05 vs. glycolysis in control 
conditions.
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to the total number of crypt cells. Gen-
eral morphology was examined on H&E 
stained sections and quantification of the 
vascular area, retinal layer thickness,26 
GFAP+, CD31+, CD105+, and CD45+ area 
was done using NIH Image J and AxioVi-
sion (Carl Zeiss) software packages. Daily 
i.p. injections of 3PO resulted in the for-
mation of precipitates, which caused local 
peritoneal inflammation beyond 2 wk. 
Hematological profiling
Hematological profiling was performed 
using Cell Dyn 3700 equipment (Abbott 
Diagnostics). Plasma measurements of 
renal, liver and heart parameters were per-
formed in the clinical laboratory of the 
university hospital of Leuven. 
Cytotoxicity agent
Mice were treated with single doses of 
cisplatin or doxorubicin via i.p. injection 
(7 mg/kg). Capecitabine (250 mg/kg) and 
sorafenib (30 mg/kg) were provided daily 
via gavage. 3PO treatment was started 
the first day after initiation of cytotoxic 
therapy. Blood samples were obtained for 
hematological profiling at day 0, 3, 7, 10, 
14, and 17 d. 
Vessel leakiness
Mice were injected daily with 3PO (50 
mg/kg/day) for 4 d. For analysis of vessel 
leakiness, Evans blue (16 h) or FITC dex-
tran (10 min; MW 40 000) was injected 
into the tail vein after which mice were 
euthanized and organs dissected. Evans 
blue leakiness in organs was quantified 
spectrophotometrically after formamide 
based extraction of the dye. FITC dextran 
leakiness outside the vessels was quanti-
fied on cryosections counterstained for the 
blood vessel marker CD105. 
Vessel perfusion
Vessel perfusion in the retinal vascu-
lature was determined after retrobulbar 
FITC dextran injection (3PO treatment: 
50 mg/kg/day for 15 d). All analyses were 
done with NIH ImageJ and AxioVision 
(Carl Zeiss) software packages.
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